Side Navigation

R&D

Pipeline

Summary

At LegoChem Biosciences we focus on the development of next generation novel therapeutics utilizing its proprietary medicinal drug discovery technology ‘LegoChemistry™’ & Antibody-Drug Conjugate platform technology ‘ConjuAll™’. Since its foundation in 2006, LCB has focused on the research and development of ADC, antibiotics, anticoagulants & anticancer therapeutics based on proprietary platform technologies.

Antibody-Drug Conjugate

  Partner Discovery Preclinical Phase I Phase II Phase III Approval
LCB14-0110
HER2
후보물질 전임상        
LCB14-15nn
Undisclosed
후보물질          
LCB14-17nn
Mesothelin
후보물질          
LCB14-XXXX
Multi targets
후보물질          
LCB14-15XX
CD37
후보물질          
LCB14-XXXX
Undisclosed
후보물질          
LCB14-15XX
Solid Tumor
후보물질          
LCB14-19nn
EGFRvIII
후보물질          
LCB14-2nnn
Undisclosed (PNS)
후보물질          

Antibiotics

  Partner Discovery Preclinical Phase I Phase II Phase III Approval
LCB01-0371 (PO)
MDR-TB
후보물질 전임상 임상 1상 임상 2상    
LCB01-0371 (IV)
MRSA, VRE
후보물질 전임상 임상 1상      
LCB10-0200
Gram Negative
후보물질 전임상        
LCB18-0055
β-lactamase inhibitor (BLI)
후보물질          

Anticoagulants

  Partner Discovery Preclinical Phase I Phase II Phase III Approval
Nokxaban
Factor Xa
후보물질 전임상 임상 1상 임상 2상    

Anticancer

  Partner Discovery Preclinical Phase I Phase II Phase III Approval
ALK Inhibitor
Multiple
후보물질